|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Low levels of SIRT4 expression was correlated with tumor node metastasis (TNM) stage, histological type of tumor (adenocarcinoma), lymph nodal status, Ki-67 (proliferation index) and poor overall survival.
|
27941873 |
2017 |
|
Adenocarcinoma, Endometrioid
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicated that SIRT4 may be involved in the development of endometrioid adenocarcinoma and is a promising target for both the diagnosis and potential therapy of endometrioid adenocarcinoma.
|
28582846 |
2017 |
|
Adult Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, SIRT4 loss in a genetic mouse model of Myc-induced Burkitt lymphoma, Eμ-Myc transgenic mouse, greatly accelerates lymphomagenesis and mortality.
|
24368766 |
2014 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to elucidate the effect of sirtuin 4 on aging of SMCC7721 liver cancer cell line, to underlying molecular mechanism and potential application in clinics.
|
28387906 |
2017 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.
|
24368766 |
2014 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, SIRT4 enhances the sensitivity of breast cancer cells to tamoxifen.
|
31573734 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, Sirtuin family of genes shows differential expressions in breast cancer tissues and cells and SIRT1 and SIRT4 seem to play key tumor suppressor roles in breast cancer development.
|
27080717 |
2016 |
|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, SIRT4 loss in a genetic mouse model of Myc-induced Burkitt lymphoma, Eμ-Myc transgenic mouse, greatly accelerates lymphomagenesis and mortality.
|
24368766 |
2014 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
SIRT4 is well-known for its deacetylase activity in energy metabolism, but little is known about its roles in carcinogenesis.
|
27941873 |
2017 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
It is known that SIRT4 has deacetylase activity and plays a role in energy metabolism, but little is known about its possible role in carcinogenesis.
|
30992675 |
2019 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
SIRT4 inhibited lung cancer cell proliferation, blocked the cell cycle and repressed cell invasion and migration.
|
27941873 |
2017 |
|
Carcinoma, Endometrioid
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicated that SIRT4 may be involved in the development of endometrioid adenocarcinoma and is a promising target for both the diagnosis and potential therapy of endometrioid adenocarcinoma.
|
28582846 |
2017 |
|
Cardiac Hypertrophy
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The aim of the present study was to investigate the role of Sirt4 in the pathogenesis of pathological cardiac hypertrophy and the molecular mechanism by which Sirt4 regulates mitochondrial oxidative stress.
|
27099261 |
2017 |
|
Cardiomegaly
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity.
|
27099261 |
2017 |
|
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SIRT4 exhibits a tumor suppressor function in human NB and inhibits mitochondrial metabolism and SIRT1 expression in tumor cells, thereby reducing the energy metabolism of tumor cells.
|
30519106 |
2018 |
|
Childhood Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, SIRT4 loss in a genetic mouse model of Myc-induced Burkitt lymphoma, Eμ-Myc transgenic mouse, greatly accelerates lymphomagenesis and mortality.
|
24368766 |
2014 |
|
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SIRT4 exhibits a tumor suppressor function in human NB and inhibits mitochondrial metabolism and SIRT1 expression in tumor cells, thereby reducing the energy metabolism of tumor cells.
|
30519106 |
2018 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Thus, these results suggest that SIRT4 may be a promising therapeutic target in CRC.
|
30008852 |
2018 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
SIRT4 has a tumour-suppressive function and may serve as a novel therapeutic target in colorectal cancer.
|
26086877 |
2015 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Together, these results highlight the prognostic value of SIRT4 in colorectal cancer and the potential application of SIRT4 in colorectal cancer treatment.
|
26986234 |
2016 |
|
Coronary Arteriosclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Corrigendum to "Circulating Levels of Sirtuin 4, a Potential Marker of Oxidative Metabolism, Related to Coronary Artery Disease in Obese Patients Suffering from NAFLD, with Normal or Slightly Increased Liver Enzymes".
|
30186546 |
2018 |
|
Coronary Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Amelioration of myocardial ischemia-reperfusion injury by SIRT4 involves mitochondrial protection and reduced apoptosis.
|
29777709 |
2018 |
|
Coronary Artery Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Corrigendum to "Circulating Levels of Sirtuin 4, a Potential Marker of Oxidative Metabolism, Related to Coronary Artery Disease in Obese Patients Suffering from NAFLD, with Normal or Slightly Increased Liver Enzymes".
|
30186546 |
2018 |
|
Coronary heart disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Corrigendum to "Circulating Levels of Sirtuin 4, a Potential Marker of Oxidative Metabolism, Related to Coronary Artery Disease in Obese Patients Suffering from NAFLD, with Normal or Slightly Increased Liver Enzymes".
|
30186546 |
2018 |
|
Cytochrome-c Oxidase Deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
We assayed intracellular levels of sirtuin 1 and the mitochondrial sirtuins SIRT3 and SIRT4 in human fibroblasts from patients with COX- deficiency.
|
29059204 |
2017 |